Healthcare provider profile · identity verified

Ralene Wiberg, MD

Family Practice · NAMPA, ID · NPI 1912956806

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	592	225
Amlodipine Besylate	Amlodipine Besylate	336	126
Lisinopril	Lisinopril	287	100
Losartan Potassium	Losartan Potassium	202	76
Levothyroxine Sodium	Levothyroxine Sodium	189	63
Simvastatin	Simvastatin	143	45
Metformin Hcl	Metformin Hcl	136	45
Albuterol Sulfate Hfa	Albuterol Sulfate	106	60
Tamsulosin Hcl	Tamsulosin Hcl	95	35
Alendronate Sodium	Alendronate Sodium	91	37
Hydrochlorothiazide	Hydrochlorothiazide	86	30
Metoprolol Tartrate	Metoprolol Tartrate	78	26
Ozempic	Semaglutide	77	16
Arexvy	Rsvpref3 Antigen/As01e/Pf	76	76
Metoprolol Succinate	Metoprolol Succinate	71	31
Metformin Hcl Er	Metformin Hcl	70	28
Atenolol	Atenolol	67	22
Allopurinol	Allopurinol	61	20
Rosuvastatin Calcium	Rosuvastatin Calcium	59	22
Tenivac	Tetanus-Diphtheria Toxoids/Pf	58	58
Pantoprazole Sodium	Pantoprazole Sodium	57	17
Gabapentin	Gabapentin	48	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	16
Jardiance	Empagliflozin	44	19
Zolpidem Tartrate	Zolpidem Tartrate	44	18
Clopidogrel	Clopidogrel Bisulfate	38	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	38	suppressed
Furosemide	Furosemide	38	16
Glipizide	Glipizide	36	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	36	15
Finasteride	Finasteride	35	12
Mirtazapine	Mirtazapine	34	17
Montelukast Sodium	Montelukast Sodium	34	13
Pravastatin Sodium	Pravastatin Sodium	33	14
Shingrix	Varicella-Zoster Ge/As01b/Pf	33	31
Trazodone Hcl	Trazodone Hcl	33	15
Triamcinolone Acetonide	Triamcinolone Acetonide	32	23
Carvedilol	Carvedilol	29	suppressed
Oxycodone Hcl	Oxycodone Hcl	29	14
Tramadol Hcl	Tramadol Hcl	29	11
Warfarin Sodium	Warfarin Sodium	29	suppressed
Cephalexin	Cephalexin	27	23
Ondansetron Odt	Ondansetron	27	suppressed
Prednisone	Prednisone	27	18
Xarelto	Rivaroxaban	27	11
Alvesco	Ciclesonide	26	16
Amoxicillin	Amoxicillin	24	20
Ezetimibe	Ezetimibe	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	16
Lorazepam	Lorazepam	24	14
Terazosin Hcl	Terazosin Hcl	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Mupirocin	Mupirocin	23	22
Spironolactone	Spironolactone	23	suppressed
Acyclovir	Acyclovir	22	suppressed
Colchicine	Colchicine	21	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	21	suppressed
Clobetasol Propionate	Clobetasol Propionate	20	12
Humulin N	Insulin Nph Human Isophane	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Glipizide Er	Glipizide	19	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	11
Cefpodoxime Proxetil	Cefpodoxime Proxetil	18	17
Doxycycline Monohydrate	Doxycycline Monohydrate	17	14
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	14	suppressed
Liraglutide	Liraglutide	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Digoxin	Digoxin	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Estradiol	Estradiol	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Sertraline Hcl	Sertraline Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error